Condition Guide
Peptides for Visceral Fat Reduction
Visceral fat is a cardiometabolic risk factor distinct from subcutaneous fat. Tesamorelin has FDA-level evidence for visceral fat reduction, and GLP-1/dual/triple agonists also preferentially reduce visceral depots.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
How peptides help
GHRH analogs mobilize visceral adipose tissue through GH-mediated lipolysis. Incretins reduce visceral fat as part of overall weight loss.
Peptides researched for visceral fat reduction
Tesamorelin
Strong EvidenceL515-18% visceral fat reduction in Phase III.
36 studies · GHRH Receptor Agonism
Semaglutide
Strong EvidenceL5Reduces visceral fat as component of weight loss.
630 studies · GLP-1 Receptor Agonism
Tirzepatide
Strong EvidenceL5Greater visceral fat reduction than semaglutide.
180 studies · Dual GIP/GLP-1 Agonism
AOD-9604
PreliminaryL2Lipolytic GH fragment; limited human visceral data.
23 studies · Lipolytic GH Fragment Activity
State of the evidence
Tesamorelin Phase III data specifically measured visceral adipose tissue. Incretin studies typically measure total body weight but show visceral preference in body-composition sub-analyses.
Frequently asked
Which peptide targets belly fat the most?
Tesamorelin has the most specific evidence for visceral fat reduction. Triple agonists like retatrutide produce the largest overall fat-mass reductions.
Related articles & guides
What Are Peptides? A Science-Based Introduction
Guide · 12 min
Peptides for Weight Loss: What the Research Shows
Guide · 15 min
FDA Regulation of Peptides: What You Need to Know
Guide · 10 min
Peptides for Women: Safety, Benefits, and What’s Different
Deep Dive · 14 min
Ozempic Side Effects: What 5 Years of Real-World Data Actually Shows
Safety · 15 min
Oral Wegovy Pill Gets FDA Approval: What You Need to Know
Regulatory · 7 min
Retatrutide Phase 3: Triple Agonist Delivers 71 lbs Average Weight Loss
Clinical Trials · 6 min
Semaglutide Could Cost $3/Month: Patent Expiry and Generic Timeline
Industry · 6 min
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
Research · 9 min
Related conditions
Weight Loss
Peptides that reduce appetite, slow gastric emptying, and improve metabolic health for sustained weight loss.
Metabolic Syndrome
Incretin and mitochondrial peptides improve insulin sensitivity, blood pressure, and lipid profile.
Fatty Liver Disease (MASH / NAFLD)
GLP-1, dual, and triple agonists reduce hepatic fat and MASH inflammation.